Anteris Technologies Global Corp.

Anteris Technologies Global Corp. が 2026年8月12日 に発表した内容

2026年6月30日 に終了した四半期、前年同期との比較。

これは単独四半期の数字であって通年ではありません——このサイトの他の場所の数字は 12 か月を対象としており、はるかに大きくなります。季節性のある事業は両者の間で大きく振れます：ServiceNow は 12 月期に 20 億ドルのフリーキャッシュフローを稼ぎ、6 月期には 5 億ドルです。

比較対象はアナリスト予想ではなく前年同期です。「上振れ」「下振れ」と言うにはコンセンサス予想が必要ですが、それは当方が保有しないライセンスデータであり——間違えるくらいなら載せないほうがましです。

決算説明会

Anteris Technologies Global Corp. の決算説明会の書き起こしはありません。

経営陣の発言

“Q2 marked an important period of execution for Anteris as we advanced the PARADIGM Trial across clinical, regulatory and reimbursement milestones. During the quarter, we secured U.S. Medicare reimbursement for eligible procedures, initiated U.S. recruitment in the PARADIGM Trial, expanded active recruitment across key geographies and showcased growing clinical experience with DurAVR ® at New York Valves, a leading structural heart conference. These achievements, together with the continued strengthening of our Board, support our progress toward commercialization and our commitment to improving outcomes for patients with severe aortic stenosis,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Anteris Technologies Global Corp. の事業内容

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR ® Transcatheter Heart Valve (“THV”), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR ® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR ® THV is made using a single piece of molded ADAPT ® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT ® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR ® THV System is comprised of the DurAVR ® valve, the ADAPT ® tissue, and the balloon-expandable ComASUR ® Delivery System.

発表資料の末尾に記載された、企業自身による説明です。